Zacks Investment Research on MSN
Here's why you should retain Glaukos stock in your portfolio now
Glaukos Corporation GKOS is well-poised for growth on the back of expansion of interventional glaucoma, clinical and ...
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...
Glaukos (GKOS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Sarcone from Jefferies maintained a Buy rating on the stock and has a ...
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded ...
Thursday, Glaukos Corporation (NYSE:GKOS) reported a first-quarter adjusted EPS loss of $(0.70), up from $(0.59) a year ago, missing the consensus of $(0.57). The company reported sales of $85.6 ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...
iDose TR (travoprost intracameral implant) is a long duration prostaglandin analog approved for a single administration and indicated for the reduction of intraocular pressure (IOP) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results